According to our latest study on "Upstream Bioprocessing Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis" the market is expected to grow from US$ 9,174.09 million in 2022 and is expected to reach US$ 25,046.69 million by 2030; it is anticipated to record a CAGR of 13.4% from 2022 to 2030. The report highlights the key factors driving the upstream bioprocessing market growth and prominent players with their developments in the market.
Upstream Bioprocessing is the first stage of the bioprocess. The upstream phase includes processes such as cell line development, media development, and cultivation.
Based on product type, the upstream bioprocessing market is segmented into bioreactors and fermenters, cell culture media, filters, bags and containers, and others. The bioreactors/fermenters segment held the largest share of the upstream bioprocessing market 2022. Moreover, the cell culture segment is anticipated to register a significant CAGR during 2022-2030. Bioreactors and fermenters serve as core vessels in which cells and microorganisms are grown for various therapeutic and Bioprocessing applications involving the expression and production of biologically derived compounds. These systems are engineered to provide an optimal environment for cell growth, incorporating precise control over parameters such as temperature, pH, dissolved oxygen, and agitation. These are critical for cultivating cells and microorganisms in large-scale bioprocessing operations.
Based on workflow, the upstream bioprocessing market is classified into media preparation, cell culture, and cell separation. The cell separation segment held the largest share of the upstream bioprocessing market in 2022. It is further anticipated that a significant CAGR will be registered from 2022 to 2030. Cell separation is the initial stage of segregating protein products (cells) from the culture. The amount and quality of the product collected in the bioreactors will determine whether to terminate the cell culture, which is an important decision.
The global upstream bioprocessing market is classified into single-use and multi-use based on usage type. The single-use segment held a larger share of the market in 2022. The same segment will record a significant CAGR in the upstream bioprocessing market during 2022-2030. The upstream bioprocessing market has experienced a transformative shift with the widespread adoption of single-use technologies. Single-use systems, including bioreactors, bags, and connectors, have gained prominence for their flexibility, cost-effectiveness, and reduced risk of cross-contamination. These disposable components replace traditional stainless-steel equipment, offering a more agile and scalable approach to bioproduction. The single-use trend accelerates process development, minimizes cleaning and validation efforts, and facilitates quick changeovers between production runs.
The upstream bioprocessing market is segmented into in-house and outsourced based on mode. In 2022, the in-house segment held a larger market share. The outsourced segment is expected to record a higher CAGR during 2022-2030. In-house manufacturing is gaining traction in the upstream bioprocessing market as biopharmaceutical companies seek greater control over their production processes. Establishing in-house upstream bioprocessing facilities enables companies to tailor processes to their needs, ensuring a more customized and efficient approach. This move often involves investment in state-of-the-art bioreactors, cell culture systems, and associated technologies.
Thermo Fisher Scientific Inc., Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc., Entegris Inc., and PBS Biotech Inc. are among the leading companies operating in the global Upstream Bioprocessing market.
Companies operating in the upstream bioprocessing market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the upstream bioprocessing market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall upstream bioprocessing market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.
- In December 2023, Merck acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. The purchase boosts Merck's upstream therapeutic protein portfolio, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
- In October 2023, Getinge AB acquired High Purity New England, Inc. for US$ 120 million. By the end of 2024, the company will fully integrate High Purity New England, Inc. The acquisition has helped Getinge AB acquire a comprehensive range of proprietary and distributed products from drug discovery, upstream and downstream processing, and fill-and-finish.
- In January 2023, Sartorius collaborated with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
- In February 2022, Thermo Fisher Scientific In announced an expansion for its Bioprocessing. The company has invested US$40 million to construct and maintain a manufacturing plant for single-use technologies in Millersburg, Pennsylvania. The expansion was part of a multi-year, US$ 650 million investment to improve the company's capacity to produce Bioprocessing in a flexible, scalable, and dependable manner.
- In March 2021, Thermo Fisher Scientific Inc. launched HyPerforma DynaDrive S.U.B. in different volumes, 3,000 L and 5,000 L models. Thermo Fisher Scientific's largest commercially accessible S.U.B., the first-of-its-size 5,000 L S.U.B., allows biopharmaceutical businesses to incorporate single-use technologies into large-scale bioprocesses, such as cGMP manufacture at very high cell density and perfusion cell culture.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com